Concepedia

Luzelena Caro

LC

32

Publications

1.3K

Citations

20

H-Index

1994

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Texas Liver Institute

The University of Texas Health Science Center at San Antonio

Celerion (United States)

University of Florida

Luzelena Caro is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, virology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

1994–2024

32

Publications

32

Pitavastatin is a more sensitive and selective organic anion‐transporting polypeptide<scp>1B</scp>clinical probe than rosuvastatin

Thomayant Prueksaritanont, Xiaoyan Chu, Raymond Evers et al. · British Journal of Clinical Pharmacology · 2014 · 162 citations · Full text

Force Generation by Cytoskeletal Filament End-Tracking Proteins

Richard B. Dickinson, Luzelena Caro, Daniel L. Purich · Biophysical Journal · 2004 · 134 citations · Full text

, , +9

Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression

Brett Lauring, Andrew K.P. Taggart, James R. Tata et al. · Science Translational Medicine · 2012 · 125 citations

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

Hiromitsu Kumada, Yoshiyuki Suzuki, Yoshiyasu Karino et al. · Journal of Gastroenterology · 2016 · 76 citations · Full text

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

Luzelena Caro, David P. Nicolau, Jan J. De Waele et al. · Journal of Antimicrobial Chemotherapy · 2020 · 64 citations · Full text

Rows per page

1–5 of 32